S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute, life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical speciallved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. This first part focuses on the diagnostic aspects, the initial management as well as the immunomodulating systemic therapy.

Authors

Institutions

Publication Details

Journal
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Published
2024-09-23
DOI
https://doi.org/10.1111/ddg.15515
Citations
13
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
5.82

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy

Thorsten Annecke, Tobias Klein, Annette Stolle, Christina Schut et al.
13 citations
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Drug-Induced Adverse Reactions
5.82
article

S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy

Thorsten Annecke, Tobias Klein, Annette Stolle, Christina Schut, Katharina Boch, Lars E. French, Bettina Wedi, Heike L. Rittner, Johannes M. Weiss, Ruben Heuer, Alexander Nast, Marcus Lehnhardt, Nicos Marathovouniotis, Stefan Schnitzler, Philipp Mandel, Philip Maier, Maja Mockenhaupt, Katharina Rall, Uwe Pleyer, Anja Miriam Boos, Silke Hofmann, Frank Sander, Yvonne Liß, Marie Pradeau, Hans Mittelviefhaus, Artem Vorobyev, Jochen Gille, Mirjana Ziemer, Maren Paulmann, Verena Gundlach, Finnja Marlok, Maximilian Zepp, Björn Behr, P. Höger, Knut Brockow, Siegbert Rieg, Bernd Hartmann
article en
13 citations

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute, life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical speciallved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. This first part focuses on the diagnostic aspects, the initial management as well as the immunomodulating systemic therapy.

JDDG Journal der Deutschen Dermatologischen GesellschaftVol. 22(10)
Goethe University Frankfurt (DE), University of Kaiserslautern (DE), Witten/Herdecke University (DE), Justus-Liebig-Universität Gießen (DE), Klinikum St. Georg (DE), University Medical Center Freiburg (DE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Katholisches Kinderkrankenhaus Wilhelmstift (DE), Helios Klinikum Krefeld (DE), Unfallkrankenhaus Berlin (DE), University Hospital Schleswig-Holstein (DE), Helios Universitätsklinikum Wuppertal (DE), University Children's Hospital Tübingen (DE), University Hospital Leipzig (DE), Universitätsklinikum Würzburg (DE), Klinikum Ludwigshafen (DE), University Hospital Frankfurt (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), BG University Hospital Bergmannsheil Bochum (DE), Kliniken Essen-Mitte (DE), University Hospital Cologne (DE), University Hospital Ulm (DE), Technical University of Munich (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), RWTH Aachen University (DE), Ruhr University Bochum (DE), University of Lübeck (DE)
Gemeinsame Bundesausschuss
Openalex Percentile: Top 3%
Drug-Induced Adverse Reactions
5.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.